Indivi secures CHF 15 million

Based in Basel, Indivi is developing digital biomarkers and digital health technologies (DHT) and precision measurements to accelerate neuroscience drug development and personalized care in neurodegenerative and neuroimmune diseases. Their DHT tools are used to transform smartphones and other off-the-shelf devices into measurement systems that can capture motor, cognitive, vision, and voice-based endpoints with validated pipelines for data quality and feature extraction. These endpoints are suitable for randomized trials and regulatory science as they can be used to de-risk development by enabling more precise, continuous, and context-rich observations than traditional clinical assessments.

Ava Investors has led the company’s recent funding round, resulting in a CHF 15 million capital increase. The funding will enable to start in 2026 a proof-of-concept trial to identify functional and electrophysiological biomarkers with superior pharmacodynamic responses in the setting of Alzheimer’s disease modification by β-amyloid-depleting therapies. The results of this trial may establish novel and more responsive biomarkers which could increase the likelihood of obtaining definitive signals of treatment efficacy in early-stage AD trials.

“The field of neurodegeneration remains one of the toughest challenges in medicine. We are thrilled to bolster our efforts to augment the success rate of promising assets to reach the Proof-of-Concept stage, where conventional endpoints lack the sensitivity needed to detect early treatment effects,” said Shibeshih Belachew, Chief Medical Officer of Indivi.

“Our mission is to make measurable what is not so, by capturing early treatment benefits on complex neurological disease traits through accessible deep phenotyping software technologies,” said Guilhem Dupont, CEO of Indivi.

(Press release/RAN)